Preventing and treating Pneumocystis pneumonia in immunocompromised patients
Prevention and Treatment of Pneumocystis Pneumonia
This study is looking at how a new vaccine can help prevent Pneumocystis pneumonia, a serious lung infection that affects people with weakened immune systems, like those who have had organ transplants or are undergoing cancer treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Georgia NIH-funded |
| Lab location | 1 site (Athens, United States) |
| Project ID | NIH-10812365 on NIH RePORTER |
What this research studies
This research focuses on Pneumocystis pneumonia (PCP), a serious lung infection caused by a fungal pathogen that primarily affects individuals with weakened immune systems, such as organ transplant recipients and cancer patients. The study aims to develop a vaccine to prevent PCP and improve treatment strategies for those already infected. Using non-human primate models, researchers will evaluate the effectiveness of a recombinant protein vaccine that has shown promise in generating strong immune responses. The ultimate goal is to enhance the health outcomes of immunocompromised individuals by reducing the incidence and severity of PCP.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who are immunocompromised due to conditions such as organ transplants, cancer treatments, or advanced age.
Not a fit: Patients with fully functioning immune systems or those not at risk for Pneumocystis pneumonia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the risk of Pneumocystis pneumonia in vulnerable patient populations, leading to better health outcomes and quality of life.
How similar studies have performed: Previous studies have shown success with similar vaccine approaches in generating protective immunity against Pneumocystis pneumonia in animal models.
Where this research is happening
Athens, United States
- University of Georgia — Athens, United States (Active)
Researchers
- Principal investigator: Norris, Karen a — University of Georgia
- Study coordinator: Norris, Karen a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.